Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TVORLANDO, FL / ACCESS Newswire / September 11, 2026 / RedChip Companies will air interviews with Anixa Biosciences Inc. (
NASDAQ:ANIX) and Nexalin Technology Inc. (
NASDAQ:NXL) on the RedChip Small Stocks, Big Money™ show, a sponsored television program airing on Bloomberg TV this Saturday, September 12, at 7:00 p.m. Eastern Time (ET), and on CNBC this Sunday, September 13, at 11:00 a.m. ET. Bloomberg TV is available in an estimated 73 million homes across the United States, and CNBC is available in approximately 90 million U.S. households.
Nexalin Technology Announces Reverse Stock SplitHOUSTON, TX, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), announces that its board of directors has approved a 1-for-30 reverse stock split of the Company’s common stock, to ensure continued compliance with the Nasdaq bid-price rule. The Company’s stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios.
Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ PlatformDr. Victor Fontenelle Bastos de Lima, an investigator on Nexalin’s recently completed Brazilian clinical study, received the Young Researcher Award at BRAIN 2026 – Congress on Brain, Behavior and Emotions, held in Porto Alegre, Brazil
Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and InsomniaNewly issued U.S. patent expected to provide core intellectual property protection through 2042, further strengthening Nexalin’s proprietary position in non-invasive frequency-based deep-brain neurostimulation
Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal TrialAcquisition gives Nexalin control of AI-integrated remote patient-monitoring, clinical data-capture and virtual-care infrastructure already deployed at UCSD
Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic InsomniaPublication reports statistically significant improvement in sleep quality following treatment with Nexalin’s 15 mA, 77.5 Hz stimulation approach, with no meaningful improvement in the sham group
Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment160-participant, triple-blinded, sham-controlled study designed to support planned De Novo FDA submission for moderate-to-severe insomnia
RedChip's Biotech Investor Conference Replays Now AvailableORLANDO, FL / ACCESS Newswire / April 20, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced that on-demand replays from its Biotech Resurgence: Platforms and Pipelines of Today's Innovators investor conference, held April 16, 2026, are now available.
Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and ChinaCompany Designing FDA Application Amendments and U.S. Clinical Strategy Leveraging Extensive Real-World Neurostimulation Data Sets Reflecting Broad Clinical Experiences
Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21ORLANDO, FL, April 14, 2026 (GLOBE NEWSWIRE) -- RedChip Companies will host an investor webinar on April 21, 2026, at 4:15 p.m. ET with Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW).
Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female AdolescentsBMC Psychiatry publication reports statistically significant reductions in self-injury behaviors and depressive symptoms, with brain-network findings further supporting Nexalin’s differentiated, non-invasive DIFS approach
RedChip Showcases Public Companies Driving Biotech Innovation at April 16 Virtual Investor ConferenceORLANDO, FL / ACCESS Newswire / April 2, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced its upcoming virtual investor conference, Biotech Resurgence: Platforms and Pipelines of Today's Innovators, taking place April 16, 2026, from 9:30 a.m. to 4:00 p.m. ET.
Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market150-Patient, Triple-Blinded, Sham-Controlled Study Designed to be Executed in Collaboration with Lindus Health to Support Future FDA Submission for Drug-Free Insomnia Treatment
Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological DisordersMultiple new federal actions highlight deep brain neurostimulation as a high-priority emerging therapy for TBI, PTSD, stroke recovery, and Alzheimer’s disease
Nexalin Technology and First Phosphate Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVORLANDO, FL / ACCESS Newswire / February 13, 2026 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and First Phosphate Corp. (CSE:PHOS)(OTCQX:FRSPF)(FSE:KD0) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, February 14, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer’s, Mood Disorders, TBI & PTSD CareNew digital health platform being launched in partnership with UCSD allows remote physician-monitored neurotherapy subscription models to expand reach, lower cost, and break down treatment stigma for brain-health disorders
